Published By : 23 Mar 2016 | Published By : QYRESEARCH
The global market for noninvasive prenatal testing market has seen rapid development in the past few years owing to the rising demand from global consumers who are increasingly more aware about the benefits of these tests over conventional prenatal tests such as nuchal translucency (NT) scan, maternal serum screening, chorionic villus sampling (CVS), and amniocentesis. The several advantages of noninvasive prenatal testing over conventional prenatal tests include accuracy, safety, and no risk of miscarriage.
Noninvasive prenatal tests are the genetic screening tests undertaken to rule out the possibilities of occurrence of genetic issues such as monosomy X, trisomy 18, trisomy 21, and trisomy 13 commonly observed in the fetuses of pregnant women over the age of 35 years, which are also referred to as high risk pregnant women owing to the age factor.
Tests such as Panorama, MaterniT21 PLUS, PrenaTest, BambniTest, Harmony, verifi, and NIFTY are some of the most popular noninvasive prenatal tests in the global market presently. These tests are used for the direct analysis of cell-free fetal DNA in the blood of pregnant women.
Owing to the ability of today’s technologically advanced noninvasive prenatal tests in detecting the presence of chromosomal deformities in fetuses during periods as early as 9 to 10 weeks of gestation and the rising trend of bearing children at advanced maternal ages have significantly contributed to the rising demand for a number of noninvasive prenatal tests across the globe in the past few years. The increased popularity of noninvasive prenatal tests among gynecologists and high risk pregnant women are also some of the major factors driving the global noninvasive prenatal testing market.
However, some regulatory and ethical concerns are projected to pose certain challenges to the growth of the global noninvasive prenatal tests market. Several professional committees across the globe believe that the implementation of noninvasive prenatal tests and the rising uptake of noninvasive prenatal tests can pose the risk of abortions. Therefore, the market is projected to be restrained to a certain extent over the next few years.